Bionic Organs with Silicon Nanopore Membranes

Bionic Organs with Silicon Nanopore Membranes

Share

One of the challenges to building artificial organs is finding or creating suitable materials for use in such devices. If the device contains living cells, then those cells need to receive nutrients from, exchange gases with, and send cellular waste products into blood. In addition, the cells should also respond appropriately to circulating regulatory signals, such as hormones, and release regulatory molecules into the circulation. Efforts are underway to develop implantable artificial kidney devices and pancreas devices to replace the function of these organs (Figure 1). To replace dialysis for people with end-stage renal disease (ESRD), the cells need to filter the blood for molecules that need to be eliminated from the body. To replace lost pancreas function, the cells need to detect glucose and release insulin into blood.

kidney_pancreas
Figure 1. Anatomy of the kidney and pancreas. Illustrations from OpenStax College [CC BY 3.0 (http://creativecommons.org/licenses/by/3.0)]
Cells can interact with the blood because of the properties of the cell’s plasma membrane. So, one way to achieve this interaction is to create a membrane that has properties like those of the plasma membrane. In addition to having the appropriate permeability, these membranes need to be nontoxic to cells and need to be durable. They cannot trigger an immune response or become blocked by abundant proteins. Silicon nanopore membranes formed on a silicon support structure and coated with polyethylene glycol (PEG) have most of the right properties, except that PEG is not durable and breaks down in days. These membranes are composed of silicon and have very small slit-shaped openings that are only nanometers in size. To put this size into perspective, DNA molecules are 1-2 nanometers wide. Indeed, some researchers are using silicon nanopore membranes to develop artificial kidneys and to protect transplanted pancreas tissue from immune destruction.

For artificial kidneys, the ideal arrangement utilizes the pressure of the heart beat to push blood through the membrane and into contact with the kidney cells in the artificial kidney device. This means that the artificial kidney device needs to be placed within the circulatory system, where it must withstand the hemodynamic pressures associated with normal variations in blood pressure. Additionally, the device cannot trigger blood clots. Shuvo Roy, a researcher in the Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco (UCSF), and William Fissell, a medical doctor at Vanderbilt University Medical Center, Tennessee, are leading The Kidney Project (1) to develop such a device (Figure 2)

dialysis_artificial_kidney
Figure 2. From dialysis machines to implantable artificial kidney devices. Advances in materials science are taking medical research closer to an implantable artificial kidney that can replace the need for dialysis. Left image shows dialysis machines: By Irvin calicut (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons. Right image shows an implantable artificial kidney device: By Katzze.fritz (Own work) [CC BY-SA 4.0 (http://creativecommons.org/licenses/by-sa/4.0)], via Wikimedia Commons.
Inspired by the physiological shape of the kidney, researchers created devices with blood filters (hemofilters) in a “U” shape  with slit-shaped pores that were composed of silicon nanopore membranes and tested them in dogs (2) and pigs (3). In the study with dogs, devices containing the membranes without kidney cells were placed into the circulatory system, the filtered blood was collected in bags connected to the device that were placed in the abdomen, and the animals moved freely after the surgery. Blood flow through the devices was assessed by ultrasound. At the end of the test period (3, 4, 5, or 8 days), the fluid bags were collected and the devices were retrieved. None of the animals had evidence of heart failure or lung damage. Some of the animals had higher amounts of fluid with higher amounts of protein in the bags than was predicted from analysis of the hydraulic properties and sizes of the pores in the membranes. However, inspection of the devices indicated that the membrane itself was intact but had become detached from the substrate. Thus, although this is problematic, it indicates that the silicon nanomembrane can withstand the pressure and forces associated with blood flow.

The second study with the pigs was performed to test a different manufacturing process for the silicon nanopore membranes with the goal of increasing the movement of molecules (diffusion) across the membrane. This process introduced a pattern to the backside, which contained the supporting material, to reduce the thickness of this support structure and enhance diffusion across the membrane. After testing diffusion using mechanical pumps, the authors attached pigs to the device as an external blood filter and collected the fluid filtered from the blood over 6 hours. The results showed an improvement over previous designs in diffusion rates and clearance of molecules that are filtered by the kidneys from the blood.

Future work will have to test alternative coatings to PEG and resolve the problem of detachment of the membrane from the support. However, these studies show the potential for advances in materials science to lead to “a surgically implantable, self-monitoring, and self-regulating bioartificial kidney” (1).

The second application of silicon nanopore membranes is quite different. In this application, the silicon nanopore membrane prevents the immune system from destroying transplanted cells. Type 1, or insulin-dependent diabetes, is caused by autoimmune attack on the β cells of the pancreas. These are the cells that produce insulin. Thus, patients with type 1 diabetes lack the cells that produce insulin/ Because the immune system targets these cells for destruction, transplantation is not a viable solution. Roy and Fissell (4, 5) are exploring the use of silicon nanopore membranes to surround the pancreas cells isolated from islets (the places in the pancreas where β cells can be found) and protect them from the toxic effects of immune cells and molecules produced by immune cells, such as pro-inflammatory cytokines. In the first study, the researchers (4) showed that the membranes had a high rate of diffusion, allowing the passage of glucose and insulin while limiting the passage of pro-inflammatory cytokines. Cytokines are much smaller than immune cells, so these membranes will also prevent the immune cells from destroying cells surrounded by these membranes. When mouse islet cells were placed between two silicon nanopore membranes, the cells were protected from the toxic effects of the cytokines added to the medium and the cells released insulin in response to the addition of glucose to the medium.

In the second study, the researchers (5) placed a bioartificial pancreas (BAP) device into pigs. Similar to the strategy for the artificial kidney, the device was connected to the circulation. Different from the artificial kidney studies, which only tested a device containing the silicon nanopore membrane without living cells, the BAP devices contained islet cells. The cells in the BAP were exposed to the molecules in the blood that could pass through the membrane in response to the pressure associated with the heartbeat. Over the 3 days of the experiment, device maintained flow and most of the islet cells survived. This short-term study provides proof-of-principle for protecting cells from immune attack using silicon nanopore membranes.

Along with progress in growing functional tissues and organoids in culture, the ability to manufacture selectively permeable membranes that are compatible for implantation (biocompatible) will lead to exciting new treatments options for patients suffering from various types of organ failure or autoimmune tissue destruction. The concept of a immunoprotective membrane for transplanted tissue may also reduce or eliminate the need for immunosuppressive therapy and expand the options for some transplant recipients.

Highlighted Articles and Resources

  1. The Kidney Project. USCF, Schools of Pharmacy and Medicine, Department of Bioengineering and Therapeutic Sciences. https://pharm.ucsf.edu/kidney (accessed on 11 September 2017)
  2. Kensinger, C., Karp, S., Kant, R., Chui, B.W., Goldman, K., Yeager, T., Gould, E.R., Buck, A., Laneve, D.C., Groszek, J.J., Roy, S., Fissell, W.H., First implantation of silicon nanopore membrane hemofilters. ASAIO J. 62, 491–495 (2016). doi:10.1097/MAT.0000000000000367 PubMed
  3. Kim, S., Feinberg, B., Kant, R., Chui, B., Goldman, K., Park, J., Moses, W., Blaha, C., Iqbal, Z., Chow, C., Wright, N., Fissell, W.H., Zydney, A., Roy, S., Diffusive silicon nanopore membranes for hemodialysis applications. PLOS ONE 11, e0159526 (2016). PubMed
  4. Song, S., Faleo, G., Yeung, R., Kant, R., Posselt, A.M., Desai, T.A., Tang, Q., Roy, S., 2016. Silicon nanopore membrane (SNM) for islet encapsulation and immunoisolation under convective transport. Sci. Rep. 6, srep23679 (2016). PubMed
  5. Song, S., Blaha, C., Moses, W., Park, J., Wright, N., Groszek, J., Fissell, W., Vartanian, S., Posselt, A.M., Roy, S., 2017. An intravascular bioartificial pancreas device (iBAP) with silicon nanopore membranes (SNM) for islet encapsulation under convective mass transport. Lab. Chip 17, 1778–1792 (2017). PubMed

Cite as: N. R. Gough, Bionic Organs with Silicon Nanopore Membranes. BioSerendipity (11 September 2017) https://www.bioserendipity.com/2017/09/11/bionic-organs-with-silicon-nanopore-membranes/.

Share